Publications by authors named "A Tsatsoulis"

Retrotransposons are invasive genetic elements, which replicate by copying and pasting themselves throughout the genome in a process called retrotransposition. The most abundant retrotransposons by number in the human genome are Alu and LINE-1 elements, which comprise approximately 40% of the human genome. The ability of retrotransposons to expand and colonize eukaryotic genomes has rendered them evolutionarily successful and is responsible for creating genetic alterations leading to significant impacts on their hosts.

View Article and Find Full Text PDF
Article Synopsis
  • - Obesity and poor metabolic health raise the risk of heart complications in adults, but identifying these issues early in children is under-researched.
  • - Researchers evaluated biomarkers like FGF21, leptin, and others in 78 kids to differentiate between healthy and unhealthy metabolic states among normal-weight and overweight/obese groups.
  • - Findings showed that higher FGF21 in normal-weight children and increased leptin in overweight/obese children can effectively identify metabolic unhealthiness, highlighting that different metabolic conditions exist in both groups.
View Article and Find Full Text PDF

Evidence suggests that genome-wide hypomethylation may promote genomic instability and cellular senescence, leading to chronic complications in people with diabetes mellitus. Limited data are however available on the Alu methylation status in patients with type 1 diabetes (T1D). : We investigated DNA methylation levels and patterns of Alu methylation in the peripheral blood of 36 patients with T1D and 29 healthy controls, matched for age and sex, by using the COmbined Bisulfite Restriction Analysis method (COBRA).

View Article and Find Full Text PDF

The aim of this study was to assess the factors associated with impaired vascular function in patients with poorly controlled type 2 diabetes (DM2) with and without overt cardiovascular disease (CVD). Ninety-five patients with DM2 and poor glycemic control were recruited and divided into two groups: Group 1, with known CVD ( = 38), and Group 2, without CVD ( = 57). Patients in Group 2 were further subdivided into those with short (<5 years, group 2b) and long (>5 years, group 2a) diabetes duration.

View Article and Find Full Text PDF